1887

Abstract

is the most frequently identified enteric pathogen in patients with nosocomial antibiotic-associated diarrhoea and pseudomembranous colitis. Several clinically isolated strains are resistant to antibiotics other than metronidazole and vancomycin. Recently, bacteriocins of lactic acid bacteria have been proposed as an alternative or complementary treatment. The aim of this study was to investigate the inhibitory effect of nisin, a bacteriocin produced by several strains of , against clinical isolates of . Nisin Z obtained from culture of subsp. biovar. was tested along with commercial nisin A. The effect of nisin A on spores was also examined. Nisin A and Z both inhibited the growth of all isolates, and MICs were estimated at 6.2 μg ml for nisin Z and 0.8 μg ml for nisin A. In addition, spores were also susceptible to nisin A (25.6 μg ml), which reduced spore viability by 40–50 %. These results suggested that nisin and hence nisin-producing strains could be used to treat -associated diarrhoea.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000202
2016-02-01
2020-01-24
Loading full text...

Full text loading...

/deliver/fulltext/jmm/65/2/169.html?itemId=/content/journal/jmm/10.1099/jmm.0.000202&mimeType=html&fmt=ahah

References

  1. Abriouel H., Maqueda M., Gálvez A., Martínez-Bueno M., Valdivia E.. 2002; Inhibition of bacterial growth, enterotoxin production, and spore outgrowth in strains of Bacillus cereus by bacteriocin AS-48. Appl Environ Microbiol68:1473–1477 [CrossRef][PubMed]
    [Google Scholar]
  2. Ali D., Lacroix C., Simard R. E., Thuault D., Bourgeois C. M.. 1995; Characterization of diacetin B, a bacteriocin from Lactococcus lactis subsp. lactis bv. diacetylactis UL720. Can J Microbiol41:832–841 [CrossRef][PubMed]
    [Google Scholar]
  3. Aslam S., Hamill R. J., Musher D. M.. 2005; Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis5:549–557 [CrossRef][PubMed]
    [Google Scholar]
  4. Ávila M., Gómez-Torres N., Hernández M., Garde S.. 2014; Inhibitory activity of reuterin, nisin, lysozyme and nitrite against vegetative cells and spores of dairy-related Clostridium species. Int J Food Microbiol172:70–75 [CrossRef][PubMed]
    [Google Scholar]
  5. Baines S. D., O'Connor R., Freeman J., Fawley W. N., Harmanus C., Mastrantonio P., Kuijper E. J., Wilcox M. H.. 2008; Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother62:1046–1052 [CrossRef][PubMed]
    [Google Scholar]
  6. Bartoloni A., Mantella A., Goldstein B. P., Dei R., Benedetti M., Sbaragli S., Paradisi F.. 2004; In-vitro activity of nisin against clinical isolates of Clostridium difficile. J Chemother16:119–121 [CrossRef][PubMed]
    [Google Scholar]
  7. Bouksaim M., Fliss I., Meghrous J., Simard R., Lacroix C.. 1998; Immunodot detection of nisin Z in milk and whey using enhanced chemiluminescence. J Appl Microbiol84:176–184 [CrossRef][PubMed]
    [Google Scholar]
  8. Breukink E., de Kruijff B.. 1999; The lantibiotic nisin, a special case or not?. Biochim Biophys1462:223–234 [CrossRef]
    [Google Scholar]
  9. CLSI 2007; Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard, 7th edn., Document M11-A7 Wayne, PA: Clinical and Laboratory Standards Institute;
    [Google Scholar]
  10. Drider D., Rebuffat S.. 2011; Prokaryotic Antimicrobial Peptides: From Genes to Applications Dordrecht: Springer;[CrossRef]
    [Google Scholar]
  11. Drummond L. J., McCoubrey J., Smith D. G. E., Starr J. M., Poxton I. R.. 2003; Changes in sensitivity patterns to selected antibiotics in Clostridium difficile in geriatric in-patients over an 18-month period. J Med Microbiol52:259–263 [CrossRef][PubMed]
    [Google Scholar]
  12. Field D., Quigley L., O'Connor P. M., Rea M. C., Daly K., Cotter P. D., Hill C., Ross R. P.. 2010; Studies with bioengineered Nisin peptides highlight the broad-spectrum potency of Nisin V. Microb Biotechnol3:473–486 [CrossRef][PubMed]
    [Google Scholar]
  13. Gut I. M., Prouty A. M., Ballard J. D., van der Donk W. A., Blanke S. R.. 2008; Inhibition of Bacillus anthracis spore outgrowth by nisin. Antimicrob Agents Chemother52:4281–4288 [CrossRef][PubMed]
    [Google Scholar]
  14. Gut I. M., Blanke S. R., van der Donk W. A.. 2011; Mechanism of inhibition of Bacillus anthracis spore outgrowth by the lantibiotic nisin. ACS Chem Biol6:744–752 [CrossRef][PubMed]
    [Google Scholar]
  15. Hammami R., Fernandez B., Lacroix C., Fliss I.. 2013; Anti-infective properties of bacteriocins: an update. Cell Mol Life Sci70:2947–2967 [CrossRef][PubMed]
    [Google Scholar]
  16. Kelly C. P., LaMont J. T.. 2008; Clostridium difficile – more difficult than ever. N Engl J Med359:1932–1940 [CrossRef][PubMed]
    [Google Scholar]
  17. Lakshminarayanan B., Guinane C. M., O'Connor P. M., Coakley M., Hill C., Stanton C., O'Toole P. W., Ross R. P.. 2013; Isolation and characterization of bacteriocin-producing bacteria from the intestinal microbiota of elderly Irish subjects. J Appl Microbiol114:886–898 [CrossRef][PubMed]
    [Google Scholar]
  18. Le Blay G., Lacroix C., Zihler A., Fliss I.. 2007; In vitro inhibition activity of nisin A, nisin Z, pediocin PA-1 and antibiotics against common intestinal bacteria. Lett Appl Microbiol45:252–257 [CrossRef][PubMed]
    [Google Scholar]
  19. Le Lay C., Akerey B., Fliss I., Subirade M., Rouabhia M.. 2008; Nisin Z inhibits the growth of Candida albicans and its transition from blastospore to hyphal form. J Appl Microbiol105:1630–1639 [CrossRef][PubMed]
    [Google Scholar]
  20. Martinez-Cuesta M. C., Bengoechea J., Bustos I., Rodriguez B., Requena T., Pelaez C.. 2010; Control of late blowing in cheese by adding lacticin 3147-producing Lactococcus lactis IFPL 3593 to the starter. Int Dairy J20:18–24 [CrossRef]
    [Google Scholar]
  21. Mathur H., O'Connor P. M., Hill C., Cotter P. D., Ross R. P.. 2013; Analysis of anti-Clostridium difficile activity of thuricin CD, vancomycin, metronidazole, ramoplanin, and actagardine, both singly and in paired combinations. Antimicrob Agents Chemother57:2882–2886 [CrossRef][PubMed]
    [Google Scholar]
  22. McAuliffe O., Ryan M. P., Ross R. P., Hill C., Breeuwer P., Abee T.. 1998; Lacticin 3147, a broad-spectrum bacteriocin which selectively dissipates the membrane potential. Appl Environ Microbiol64:439–445[PubMed]
    [Google Scholar]
  23. Meghrous J., Lacroix C., Bouksaı¨m M., LaPointe G., Simard R. E.. 1997; Note: genetic and biochemical characterization on nisin Z produced by Lactococcus lactis ssp. lactis biovar. diacetylactis UL 719. J Appl Microbiol83:133–138 [CrossRef][PubMed]
    [Google Scholar]
  24. Mota-Meira M., LaPointe G., Lacroix C., Lavoie M. C.. 2000; MICs of mutacin B-Ny266, nisin A, vancomycin, and oxacillin against bacterial pathogens. Antimicrob Agents Chemother44:24–29 [CrossRef][PubMed]
    [Google Scholar]
  25. Mulders J. W. M., Boerrigter I. J., Rollema H. S., Siezen R. J., de Vos W. M.. 1991; Identification and characterization of the lantibiotic nisin Z, a natural nisin variant. Eur J Biochem201:581–584 [CrossRef][PubMed]
    [Google Scholar]
  26. Mutlu E., Wroe A. J., Sanchez-Hurtado K., Brazier J. S., Poxton I. R.. 2007; Molecular characterization and antimicrobial susceptibility patterns of Clostridium difficile strains isolated from hospitals in south-east Scotland. J Med Microbiol56:921–929 [CrossRef][PubMed]
    [Google Scholar]
  27. Nerandzic M. M., Donskey C. J.. 2013; Activate to eradicate: inhibition of Clostridium difficile spore outgrowth by the synergistic effects of osmotic activation and nisin. PLoS One8:e54740 [CrossRef][PubMed]
    [Google Scholar]
  28. Paredes-Sabja D., Bond C., Carman R. J., Setlow P., Sarker M. R.. 2008; Germination of spores of Clostridium difficile strains, including isolates from a hospital outbreak of Clostridium difficile-associated disease (CDAD). Microbiology154:2241–2250 [CrossRef][PubMed]
    [Google Scholar]
  29. Peláez T., Cercenado E., Alcalá L., Marín M., Martín-López A., Martínez-Alarcón J., Catalán P., Sánchez-Somolinos M., Bouza E.. 2008; Metronidazole resistance in Clostridium difficile is heterogeneous. J Clin Microbiol46:3028–3032 [CrossRef][PubMed]
    [Google Scholar]
  30. Pol I. E., van Arendonk W. G. C., Mastwijk H. C., Krommer J., Smid E. J., Moezelaar R.. 2001; Sensitivities of germinating spores and carvacrol-adapted vegetative cells and spores of Bacillus cereus to nisin and pulsed-electric-field treatment. Appl Environ Microbiol67:1693–1699 [CrossRef][PubMed]
    [Google Scholar]
  31. Rea M. C., Clayton E., O'Connor P. M., Shanahan F., Kiely B., Ross R. P., Hill C.. 2007; Antimicrobial activity of lacticin 3147 against clinical Clostridium difficile strains. J Med Microbiol56:940–946 [CrossRef][PubMed]
    [Google Scholar]
  32. Rea M. C., Sit C. S., Clayton E., O'Connor P. M., Whittal R. M., Zheng J., Vederas J. C., Ross R. P., Hill C.. 2010; Thuricin CD, a post-translationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile. Proc Natl Acad Sci U S A107:9352–9357 [CrossRef][PubMed]
    [Google Scholar]
  33. Ruhr E., Sahl H. G.. 1985; Mode of action of the peptide antibiotic nisin and influence on the membrane potential of whole cells and on cytoplasmic and artificial membrane vesicles. Antimicrob Agents Chemother27:841–845 [CrossRef][PubMed]
    [Google Scholar]
  34. Rupnik M., Wilcox M. H., Gerding D. N.. 2009; Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol7:526–536 [CrossRef][PubMed]
    [Google Scholar]
  35. Slimings C., Riley T. V.. 2014; Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother69:881–891 [CrossRef][PubMed]
    [Google Scholar]
  36. Sorg J. A., Sonenshein A. L.. 2008; Bile salts and glycine as cogerminants for Clostridium difficile spores. J Bacteriol190:2505–2512 [CrossRef][PubMed]
    [Google Scholar]
  37. Stanley J. D., Bartlett J. G., Dart B.W., IV, Ashcraft J. H.. 2013; Clostridium difficile infection. Curr Probl Surg50:302–337 [CrossRef][PubMed]
    [Google Scholar]
  38. Stevens V., Dumyati G., Fine L. S., Fisher S. G., van Wijngaarden E.. 2011; Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis53:42–48 [CrossRef][PubMed]
    [Google Scholar]
  39. Surawicz C. M., Brandt L. J., Binion D. G., Ananthakrishnan A. N., Curry S. R., Gilligan P. H., McFarland L. V., Mellow M., Zuckerbraun B. S.. 2013; Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol108:478–498 quiz 499 [CrossRef][PubMed]
    [Google Scholar]
  40. Tagg J. R., Dajani A. S., Wannamaker L. W.. 1976; Bacteriocins of gram-positive bacteria. Bacteriol Rev40:722–756[PubMed]
    [Google Scholar]
  41. Tannock G. W., Munro K., Taylor C., Lawley B., Young W., Byrne B., Emery J., Louie T.. 2010; A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology156:3354–3359 [CrossRef][PubMed]
    [Google Scholar]
  42. Wiedemann I., Breukink E., van Kraaij C., Kuipers O. P., Bierbaum G., de Kruijff B., Sahl H. G.. 2001; Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity. J Biol Chem276:1772–1779 [CrossRef][PubMed]
    [Google Scholar]
  43. Wilson K. H., Perini F.. 1988; Role of competition for nutrients in suppression of Clostridium difficile by the colonic microflora. Infect Immun56:2610–2614[PubMed]
    [Google Scholar]
  44. Wiström J., Norrby S. R., Myhre E. B., Eriksson S., Granström G., Lagergren L., Englund G., Nord C. E., Svenungsson B.. 2001; Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother47:43–50 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000202
Loading
/content/journal/jmm/10.1099/jmm.0.000202
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error